Duvelisib is a pharmaceutical active pharmaceutical ingredient (API) belonging to the phosphoinositide 3-kinase (PI3K) inhibitor class. It is a small-molecule compound developed for oncology applications and selectively inhibits PI3K-delta and PI3K-gamma signaling pathways.
Duvelisib is an orally active, selective inhibitor of PI3K-δ and PI3K-γ. These enzymes are involved in signaling pathways that regulate the growth, survival and function of immune cells. Inhibition of these pathways can affect malignant B-cell proliferation and survival.
Duvelisib is a small-molecule pharmaceutical API used in the development and manufacture of oncology formulations. It is commonly associated with pharmaceutical formulations intended for certain B-cell malignancies.
Duvelisib inhibits the catalytic activity of PI3K-delta (PI3K-δ) and PI3K-gamma (PI3K-γ). PI3K-δ is primarily expressed in hematopoietic cells, while PI3K-γ is involved in immune-cell signaling. Blocking these pathways can interfere with signaling required for malignant B-cell growth and survival.
Duvelisib has been used in oncology for the treatment of certain relapsed or refractory hematologic malignancies, including:
The approved indication, treatment line and regulatory status can vary by jurisdiction and should be verified against the applicable current regulatory labeling.
Duvelisib is a synthetic small-molecule compound supplied as a pharmaceutical-grade active ingredient. It is generally handled as a crystalline solid and has physicochemical properties characteristic of its heterocyclic chemical structure.
Duvelisib API intended for pharmaceutical manufacturing should be produced under appropriate GMP controls and tested according to applicable regulatory requirements. Quality evaluation may include identity, assay, related substances, residual solvents, water content, elemental impurities and other relevant quality attributes.
Duvelisib is a specialized oncology API associated with PI3K-targeted therapies. Pharmaceutical manufacturers and formulation developers can evaluate Duvelisib based on applicable regulatory requirements, analytical documentation, quality specifications and batch-specific Certificate of Analysis.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |
| Melting Point | 168°C – 172°C |